Literature DB >> 33388995

Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.

Gisela María Suárez1, Ana Laura Añé-Kourí2, Amnely González1, Patricia Lorenzo-Luaces1, Elia Neninger3, Eva Elena Salomón4, Leamnet Cordero4, Mauricio Catalá5, Nuris Ledón6, Karla Pereira1, Malkon Guillermo Sánchez7, Beatriz García8, Tania Crombet1, Zaima Mazorra1, Danay Saavedra9, Agustin Lage1.   

Abstract

Aging is considered the single most significant risk factor for the majority of common malignances including lung cancer. Together immunosenescence, changes occurring with aging in the immune system, and inflammaging, characterizes by a chronic, subclinical accumulation of pro-inflammatory factors, are suggested to stand at the origin of most of the diseases of the elderly, such as cancer. The aim of this study was to determine associations among lymphocyte subpopulations, pro-inflammatory cytokines and epidermal growth factor (EGF) in patients diagnosed with non-small cell lung cancer (NSCLC). Forty-six advanced NSCLC patients were enrolled. Sixteen patients with newly diagnosed and before treatment and 30 patients after first-line platinum-based chemotherapy. Peripheral blood subpopulations were studied by flow cytometry and serum concentrations of soluble factors by ELISA. The frequency of naïve CD4+ T cells, naïve B cells and central memory CD8+ T cells were significantly lower in NSCLC patients after chemotherapy, while effector memory CD4+ T cells and terminally differentiated CD8+ T cells were significantly higher. IL-1β and TNFα significantly correlated among them before and after platinum-based chemotherapy. Terminally differentiated T cells expressing CD57+ significantly correlated with TNFα and IL-1β. For the first time, associations between EGF serum levels and terminally differentiated CD4+ T cells, and memory B cells were detected. This study confirms the association among terminally differentiated lymphocytes and pro-inflammatory cytokines in patients diagnosed with lung cancer, reinforcing the interconnection between terminally differentiated lymphocytes and pro-inflammatory cytokines. Clinical trial registration number: RPCEC00000205, http://registroclinico.sld.cu/.

Entities:  

Keywords:  B cells; Epidermal growth factor; Pro-inflammatory cytokines; T cells; Terminally differentiated T cells

Mesh:

Substances:

Year:  2021        PMID: 33388995     DOI: 10.1007/s00262-020-02823-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

Review 1.  Inflamm-aging. An evolutionary perspective on immunosenescence.

Authors:  C Franceschi; M Bonafè; S Valensin; F Olivieri; M De Luca; E Ottaviani; G De Benedictis
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

Review 2.  The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity.

Authors:  Xinwen Zhang; Xin Meng; Yiyin Chen; Sean X Leng; Haiyan Zhang
Journal:  Cancer J       Date:  2017 Jul/Aug       Impact factor: 3.360

3.  Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer.

Authors:  Oscar Okwudiri Onyema; Lore Decoster; Rose Njemini; Louis Nuvagah Forti; Ivan Bautmans; Marc De Waele; Tony Mets
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 5.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

6.  Immunosenescence and gender: a study in healthy Cubans.

Authors:  Beatriz García Verdecia; Danay Saavedra Hernández; Patricia Lorenzo-Luaces; Teresita de Jesús Badía Alvarez; Idrissa Leonard Rupalé; Zaima Mazorra Herrera; Tania Crombet Ramos; Agustín Lage Dávila
Journal:  Immun Ageing       Date:  2013-04-30       Impact factor: 6.400

Review 7.  Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.

Authors:  Zhi-Chun Ding; Gang Zhou
Journal:  Clin Dev Immunol       Date:  2012-02-06

8.  CD27- IgD- B cell memory subset associates with inflammation and frailty in elderly individuals but only in males.

Authors:  Tapio Nevalainen; Arttu Autio; Laura Kummola; Tanja Salomaa; Ilkka Junttila; Marja Jylhä; Mikko Hurme
Journal:  Immun Ageing       Date:  2019-08-13       Impact factor: 6.400

Review 9.  Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?

Authors:  Tamas Fulop; Anis Larbi; Gilles Dupuis; Aurélie Le Page; Eric H Frost; Alan A Cohen; Jacek M Witkowski; Claudio Franceschi
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

Review 10.  The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks.

Authors:  Jan R Aunan; William C Cho; Kjetil Søreide
Journal:  Aging Dis       Date:  2017-10-01       Impact factor: 6.745

View more
  3 in total

1.  Exploring potential targets of Actinidia chinensis Planch root against hepatocellular carcinoma based on network pharmacology and molecular docking and development and verification of immune-associated prognosis features for hepatocellular carcinoma.

Authors:  Meilin Qu; Tao Han; Xiaoquan Chen; Qingqing Sun; Qing Li; Mingfang Zhao
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study.

Authors:  An-Wen Xiong; Jue-Min Fang; Sheng-Xiang Ren; Wei Li; Jing Wang; Yu Zhao; Guo-You Chen; Qing Xu; Cai-Cun Zhou
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

3.  Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Gisela María Suárez; Mauricio Catalá; Yadira Peña; Susana Portela; Ana Laura Añé-Kourí; Amnely González; Patricia Lorenzo-Luaces; Manuel Díaz; María de Los A Molina; Karla Pereira; Jenysbel de la C Hernández; Raúl Ramos; Mary Carmen Reyes; Nuris Ledón; Zaima Mazorra; Tania Crombet; Agustin Lage; Danay Saavedra
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.